Vaccinating the inflammatory bowel disease patient

Expert Review of Gastroenterology and Hepatology

Volumn 9, Issue 1, 2015, Pages 91-102

  Desalermos, Athanasios P ^a   Farraye, Francis A ^a   Wasan, Sharmeel K ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

Crohn's disease; hepatitis A; hepatitis B; HPV; immunocompromised; infections; inflammatory bowel disease; PCV 13; PPSC23; travel; ulcerative colitis; vaccination; varicella; zoster

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BCG VACCINE; CERTOLIZUMAB PEGOL; CHICKENPOX VACCINE; CORTICOSTEROID; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; GOLIMUMAB; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOMODULATING AGENT; INFLIXIMAB; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NATALIZUMAB; PNEUMOCOCCUS VACCINE; TETANUS TOXOID; VARICELLA ZOSTER VACCINE; VEDOLIZUMAB; WART VIRUS VACCINE; BACTERIAL VACCINE; IMMUNOSUPPRESSIVE AGENT; VIRUS VACCINE;

CHICKENPOX; CROHN DISEASE; DIPHTHERIA; DRUG SAFETY; GASTROENTEROLOGIST; HAEMOPHILUS INFECTION; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INFLAMMATORY BOWEL DISEASE; INFLUENZA; INFLUENZA VACCINATION; PNEUMOCOCCAL INFECTION; REVIEW; TETANUS; TRAVEL; ULCERATIVE COLITIS; UTERINE CERVIX DYSPLASIA; VACCINATION; BACTERIAL INFECTIONS; IMMUNIZATION; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; MICROBIOLOGY; RISK FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS DISEASES;

BACTERIAL INFECTIONS; BACTERIAL VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; RISK FACTORS; TREATMENT OUTCOME; VACCINATION; VIRAL VACCINES; VIRUS DISEASES;

EID: 84918799128     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.934672     Document Type: Review

References (93)

1. Domm S, Cinatl J, Mrowietz U. The impact of treatment with tumour necrosis factor-Alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008;159(6): 1217-28
2. Keene JK, Lowe DK, Grosfeld JL, et al. Disseminated varicella complicating ulcerative colitis. JAMA 1978;239(1): 45-6
3. Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004;10(5):677-92
4. Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol 2010;105(6):1231
5. Dezfoli S, Melmed GY. Vaccination issues in patients with inflammatory bowel disease receiving immunosuppression. Gastroenterol Hepatol (N Y) 2013;8(8):504-12
6. Lu Y, Jacobson D, Bousvaros A. Immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2009;15(9):1417-23
7. Wasan SK, Calderwood AH, Long MD, et al. Immunization rates and vaccine beliefs among patients with inflammatory bowel disease: an opportunity for improvement. Inflamm Bowel Dis 2014; 20(2):246-50
8. Crawford NW, Catto-Smith AG, Oliver MR, et al. An Australian audit of vaccination status in children and adolescents with inflammatory bowel disease. BMC Gastroenterol 2011;11:87
9. Wilckens V, Kannengiesser K, Hoxhold K, et al. The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelines. Scand J Gastroenterol 2011;46(7-8):855-61
10. Loras C, Saro C, Gonzalez-Huix F, et al. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009;104(1): 57-63
11. Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006;101(8): 1834-40
12. Wasan SK, Coukos JA, Farraye FA. Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge. Inflamm Bowel Dis 2011; 17(12):2536-40
13. Carrera E, Manzano R, Garrido E. Efficacy of the vaccination in inflammatory bowel disease. World J Gastroenterol 2013;19(9): 1349-53
14. Agarwal N, Ollington K, Kaneshiro M, et al. Are immunosuppressive medications associated with decreased responses to routine immunizations?. a systematic review. Vaccine 2011;30(8):1413-24
15. Mamula P, Markowitz JE, Piccoli DA, et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5(7):851-6
16. Hagihara Y, Ohfuji S, Watanabe K, et al. Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease. J Crohns Colitis 2013;8(3):223-33
17. Altunoz ME, Senates E, Yesil A, et al. Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls. Dig Dis Sci 2011;57(4):1039-44
18. Dotan I, Werner L, Vigodman S, et al. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflamm Bowel Dis 2011; 18(2):261-8
19. Abdallah J, Kiran A, Tuyyab H, Jain A. Vaccination outcomes in inflammatory bowel disease. Presented at digestive disease week 2014, Chicago, Illinois, USA, 2014
20. Battafarano DF, Battafarano NJ, Larsen L, et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 1998;41(10):1828-34
21. Fields SW, Baiocco PJ, Korelitz BI. Influenza vaccinations: should they really be encouraged for IBD patients being treated with immunosuppressives?. Inflamm Bowel Dis 2009;15(5):649-51.author reply 651-42
22. Kwon OS, Park YS, Choi JH, et al A Case of Ulcerative Colitis Relapsed by Influenza Vaccination]. Korean J Gastroenterol 2007; 49(5):327-30
23. Melmed GY. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm Bowel Dis 2009;15(9):1410-16
24. Moscandrew M, Mahadevan U, Kane S. General health maintenance in IBD. Inflamm Bowel Dis 2009;15(9):1399-409
25. Rahier JF, Papay P, Salleron J, et al. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut 2011;60(4):456-62
26. Cullen G, Bader C, Korzenik JR, Sands BE. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut 2011;61(3):385-91
27. Advisory Committee on Immunization Practices. Recommended adult immunization schedule. United States, 2009. Ann Intern Med 2009;150(1):40-4
28. Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP) recommended immunization schedules for persons aged 0 through 18 years and adults aged 19 years and older - United States, 2013. MMWR Surveill Summ 2013; 62(Suppl 1):1
29. Brogan MD, Shanahan F, Oliver M, et al. Defective memory B cell formation in patients with inflammatory bowel disease following tetanus toxoid booster immunization. J Clin Lab Immunol 1987; 24(2):69-74
30. Nielsen HJ, Mortensen T, Holten-Andersen M, et al. Increased levels of specific leukocyte- And platelet-derived substances during normal anti-Tetanus antibody synthesis in patients with inactive Crohn Disease. Scand J Gastroenterol 2001; 36(3):265-9
31. Kane S. Abnormal Pap smears in inflammatory bowel disease. Inflamm Bowel Dis 2008;14(8):1158-60
32. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol 2008;103(3):631-6
33. Devon KM, Brown CJ, Burnstein M, McLeod RS. Cancer of the anus complicating perianal Crohn's disease. Dis Colon Rectum 2009;52(2):211-16
34. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009;3(2): 47-91
35. Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60(50):1705-8
36. Jacobson DL, Bousvaros A, Ashworth L, et al. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflamm Bowel Dis 2013;19(7):1441-9
37. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010;59(RR-8):1-62
38. Narula N, Yamamura DL, Marshall JK. Should my patient with inflammatory bowel disease on immunosuppressive therapy be vaccinated against influenza virus?. Can J Gastroenterol 2010;24(2):121-5
39. Lodhia N. The appropriate use of vaccines in patients with inflammatory bowel disease. J Clin Gastroenterol 2014;48(5):395-401
40. Boltin D, Gingold-Belfer R, Kimchi NA, et al. Utilization of influenza immunization in adults with Crohn's disease-A longitudinal, population-based study. Inflamm Bowel Dis 2014;20(2):240-5
41. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012;61(40):816-19
42. Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014;8(6): 443-68
43. Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004;53(9):1363-5
44. Montiel PM, Solis JA, Chirinos JA, et al. Hepatitis B virus reactivation During therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008; 28(5):718-20
45. Shale MJ. The implications of anti-Tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease. Br Med Bull 2009;92:61-77
46. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50(3):661-2
47. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006;55(RR-16): 1-33; quiz CE31-4
48. Vida Perez L, Gomez Camacho F, Garcia Sanchez V, et al [Adequate Rate of Response to Hepatitis B Virus Vaccination in Patients with Inflammatory Bowel Disease]. Med Clin (Barc) 2009;132(9):331-5
49. Coates T, Wilson R, Patrick G, et al. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther 2001;23(3): 392-403
50. Chevaux JB, Bigard MA, Bensenane M, et al. Inflammatory bowel disease and hepatitis B and C. Gastroenterol Clin Biol 2009;33(12):1082-93
51. Gisbert JP, Villagrasa JR, Rodriguez-Nogueiras A, Chaparro M. Kinetics of anti-hepatitis B surface antigen titers after hepatitis B vaccination in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19(3):554-8
52. Hepatitis B vaccines: WHO position paper - recommendations. Vaccine 2009; 28(3):589-90
53. Fonseca MO, Pang LW, de Paula Cavalheiro N, et al. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005;23(22):2902-8
54. Rey D, Krantz V, Partisani M, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000;18(13): 1161-5
55. Gisbert JP, Villagrasa JR, Rodriguez-Nogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol 2012; 107(10):1460-6
56. Gisbert JP, Menchen L, Garcia-Sanchez V, et al. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2012;35(12): 1379-85
57. Vogt TM, Wise ME, Bell BP, Finelli L. Declining hepatitis A mortality in the United States during the era of hepatitis A vaccination. J Infect Dis 2008;197(9): 1282-8
58. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999;48(RR-12):1-37
59. Bell BP, Shapiro CN, Alter MJ, et al. The diverse patterns of hepatitis A epidemiology in the United States-implications for vaccination strategies. J Infect Dis 1998; 178(6):1579-84
60. Le C. Control of hepatitis A infection in the U.S. West J Med 1999;170(6):324
61. Rosenthal P. Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults. Hepatology 2003; 37(1):44-51
62. Cardell K, Akerlind B, Sallberg M, Fryden A. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. J Infect Dis 2008; 198(3):299-304
63. Watson JC, Hadler SC, Dykewicz CA, et al. Measles, mumps, and rubella - vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998; 47(RR-8):1-57
64. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57(RR-5):1-30.quiz CE32-4
65. Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010; 202(8):1246-53
66. Marin M, Guris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56(RR-4):1-40
67. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126(1):19-31
68. Cullen G, Baden RP, Cheifetz AS. Varicella zoster virus infection in inflammatory bowel disease. Inflamm Bowel Dis 2012;18(12): 2392-403
69. Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000;95(12):3490-7
70. Leung VS, Nguyen MT, Bush TM. Disseminated primary varicella after initiation of infliximab for Crohn's disease. Am J Gastroenterol 2004;99(12): 2503-4
71. Ma C, Walters B, Fedorak RN. Varicella zoster meningitis complicating combined anti-Tumor necrosis factor and corticosteroid therapy in Crohn's disease. World J Gastroenterol 2013;19(21):3347-51
72. Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohn's disease in clinical practice at the Mayo clinic: the first 100 patients. Am J Gastroenterol 2001; 96(3):722-9
73. Kopylov U, Levin A, Mendelson E, et al. Prior varicella zoster virus exposure in IBD patients treated by anti-TNFs and other immunomodulators: implications for serological testing and vaccination guidelines. Aliment Pharmacol Ther 2012; 36(2):145-50
74. Kotton CN. Nailing down the shingles in IBD. Inflamm Bowel Dis 2007;13(9): 1178-9
75. Singh A, Englund KQ. Who should receive the shingles vaccine?. Cleve Clin J Med 2009;76(1):45-8
76. Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4(12):1483-90
77. Marehbian J, Arrighi HM, Hass S, et al. Adverse events associated with common therapy regimens for moderate-To-severe Crohn's disease. Am J Gastroenterol 2009; 104(10):2524-33
78. Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-Tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013;309(9): 887-95
79. Moutsopoulos HM, Gallagher JD, Decker JL, Steinberg AD. Herpes zoster in patients with systemic lupus erythematosus. Arthritis Rheum 1978;21(7):798-802
80. Rubin LG, Levin MJ, Ljungman P, et al. 2013;IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014;58(3):309-18
81. Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012;308(1):43-9
82. Zhang J, Delzell E, Xie F, et al. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res Ther 2011;13(5):R174
83. Gisbert JP, Chaparro M. Vaccination strategies in patients with IBD. Nat Rev Gastroenterol Hepatol 2013;10(5):277-85
84. Dubinsky M, Abraham B, Mahadevan U. Management of the pregnant IBD patient. Inflamm Bowel Dis 2008;14(12):1736-50
85. Vasiliauskas EA, Church JA, Silverman N, et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006;4(10): 1255-8
86. Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol 2013; 108(9):1426-38
87. Zelinkova Z, de Haar C, de Ridder L, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011;33(9):1053-8
88. De Boer NK, Jarbandhan SV, de Graaf P, et al. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol 2006; 101(6):1390-2
89. Christensen LA, Dahlerup JF, Nielsen MJ, et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther 2008; 28(10):1209-13
90. Gardiner SJ, Gearry RB, Roberts RL, et al. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. Br J Clin Pharmacol 2006;62(4):453-6
91. Sau A, Clarke S, Bass J, et al. Azathioprine and breastfeeding: is it safe?. BJOG 2007; 114(4):498-501
92. Centers for disease control and prevention. Travellers health. Available from: www.cdc. gov/travel
93. Visser LG. The immunosuppressed. traveler. Infect Dis Clin North Am 2012;26(3): 609-24